Clinical trial
Study of Proxinium for Treating Patients With Squamous Cell Head and Neck Cancer
NCT00272181 · Sesen Bio, Inc., Industry · Terminated
Key facts
| NCT number | NCT00272181 |
|---|---|
| Title | Study of Proxinium for Treating Patients With Squamous Cell Head and Neck Cancer |
| Official title | A Phase II, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of Proxinium in Patients With Advanced SCCHN Who Have Received at Least One Anti-Cancer Treatment Regimen for Advanced Disease |
| Lead sponsor | Sesen Bio, Inc., Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Squamous Cell Carcinoma of the Head and Neck, Carcinoma, Squamous Cell, Neoplasms, Head and Neck Neoplasms, Mouth Neoplasms, Head and Neck Cancer |
| Intervention type | Drug |
| Interventions | Proxinium |
| Enrollment | 15 |
| Start date | Jan 1, 2006 |
| Primary completion | Oct 1, 2007 |
| Completion | Oct 1, 2007 |
| First posted | Jan 4, 2006 |
| Last update posted | Dec 23, 2015 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: